DESCRIPTION

The *European Journal of Cancer (EJC)* is an international multidisciplinary oncology journal, which publishes original research, reviews, and editorial comments on basic and preclinical cancer research, translational oncology, clinical oncology - including medical oncology, paediatric oncology, radiation oncology, and surgical oncology, and cancer epidemiology and prevention.

The *EJC* is the official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European CanCer Organisation (ECCO) and the European Society of Breast Cancer Specialists (EUSOMA).

AUDIENCE

Basic and preclinical researchers, clinical oncologists (medical, paediatric, radiation, surgical), translational oncologists, cancer epidemiologists.

IMPACT FACTOR

2016: 6.029 © Thomson Reuters Journal Citation Reports 2017
ABSTRACTING AND INDEXING

BIOSIS
CAB Health
Elsevier BIOBASE
CINAHL
Cambridge Scientific Abstracts
Chemical Abstracts
Current Clinical Cancer
Current Contents/Clinical Medicine
Current Contents/BIOMED Database
Current Contents/Life Sciences
Current Contents/SciSearch Database
Current Contents/Science Citation Index
MEDLINE®
EMBASE
PASCAL/CNRS
Reference Update
Research Alert
SCISEARCH
Science Citation Index
Toxicology Abstracts
CAB Abstracts
UMI Microfilms
Scopus

EDITORIAL BOARD

Editor-in-Chief
Alexander M. M. Eggermont, Institut Gustave Roussy, Villejuif, France

Editor: Basic Science and Preclinical Research
Ulrich Keilholz, Berlin, Germany

Editor: Epidemiology and Prevention
Jan Willem Coebergh, Oegstgeest, The Netherlands

Editor: Drug Development
Jordi Rodon, Barcelona, Spain

Editor: Tumour Immunotherapy
Aurelien Marabelle, Villejuif, France

Editors: Breast Cancer
Giuseppe Curigliano, Milan, Italy
Suzette Delaloge, Villejuif, France

Editors: Gastrointestinal Cancers
Michel Ducreux, Villejuif, France
Volker Heinemann, Munich, Germany

Editor: Genitourinary Cancers
Karim Fizazi, Villejuif, France

Editor: Head and Neck Cancer
Jean-Pascal Machiels, Cliniques Universitaires Saint-Luc, Brussels, Belgium

Editor: Hemato-Oncology
Roch Houot, Rennes, France

Editor: Lung Cancer
Mary O’Brien, Sutton, UK
Editor: Gynaecological Cancers
Ignace Vergote, Leuven, Belgium

Editor: Endocrine, Sarcomas and Other Rare Tumours
Stefan Sleijfer, Rotterdam, Netherlands

Editor: Melanoma
Dirk Schadendorf, Essen, Germany

Editor: Neuro-oncology
Martin van den Bent, Rotterdam, Netherlands

Editor: Paediatric Oncology
Rob Pieters, Utrecht, Netherlands

Editorial Office
EJC Editorial Office, Elsevier Ltd, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, UK

Clinical Oncology Editorial Board
Richard Baird, Cambridge, England, UK
Raffaele Califano, Manchester, UK
Emiliano Calvo, Madrid, Spain
Fatima Cardoso, Lisbon, Portugal
Elisabeth G de Vries, Groningen, Netherlands
Adam Dicker, Philadelphia, USA
Reinhard Dummer, Zürich, Switzerland
Sara Erridge, Edinburgh, UK
Hans Gelderblom, Leiden, Netherlands
Birgit Geoerger, Villejuif cedex, France
John Haanen, Amsterdam, The Netherlands
Baktiar Hasan, Brussels, Belgium
Jean-Claude Horiot, Genolier, Switzerland
Dirk Jäger, Heidelberg, Germany
Artur Katz, São Paulo, Brazil
Paul Lorigan, Manchester, UK
Yohann Loriot, Villejuif Cedex, France
Christophe Massard, France
Kerrie McDonald, Sydney, Australia
Françoise Meunier, Brussels, Belgium
Tony Mok, Shatin, Hong Kong
Do-Hyun Nam, Seoul, South Korea
James Perry, Toronto, Canada
Achim Rody, Lübeck, Germany
Manuela Schmidinger, Wien, Austria
Jean-Charles Soria, Villejuif, France
Silvia Stacchiotti, Milan, Italy
Cora Sternberg, Rome, Italy
A.C.J. van Akkooi, Amsterdam, Netherlands
Eric Van Cutsem, MD, PhD, Leuven, Belgium
Galina Velikova, Leeds, UK
Eric Winquist, London, Canada
Timothy Yap, London, UK

Basic Science and Preclinical Research Editorial Board
Paola Allavena, Milan, Italy
John Anderson, London, UK
Massimo Broggini, Milan, Italy
Christophe Caux, Lyon, France
Manel Esteller, Barcelona, Spain
Enrico Garattini, Milano, Italy
J.M. Irish, Tennessee, USA
H.E.K. Kohrt, California, USA
John Lunec, Newcastle, UK
Antonia Maria Müller
Daniel Olive, Marseille, France
Athanasios Papavassiliou, Athens, Greece
Giorgio Parmiani, Milan, Italy
Victoria Sanz-Moreno, London, UK
Sheila Singh, Ontario, Canada
John Stagg, Quebec, Canada
Amaya Virós, Manchester, UK
Britta Weigelt, New York, USA
Nadia Zaffaroni, Milan, Italy

Epidemiology and Prevention Editorial Board
Philippe Autier, Lyon, France
Marianne Berwick, NM, USA
Nirmala Bhoo Pathy, Kuala Lumpur, Malaysia
Paolo Boffetta, New York, USA
Cristina Bosetti, Milan, Italy
Emanuele Crocetti, Florence, Italy
Esther de Vries, Bogota, Colombia
Christine Friedenreich, Calgary, Alberta, Canada
Gemma Gatta, Milan, Italy
Iris Lansdorp-Vogelaar, Rotterdam, Netherlands
Marc Maynadié, Dijon, France
Henrik Møller, London, UK
Eleni Petridou, Athens, Greece
Marjanka Schmidt, Amsterdam, Netherlands
Isabelle Soerjomataram, Lyon, France
Lonneke van de Poll-Franse, Eindhoven, Netherlands

Paediatric Oncology Editorial Board
Christophe Bergeron, Lyon, France
Eric Bouffet, Ontario, Canada
Mitchell Cairo, New York, USA
Guillermo Chantada, Buenos Aires, Argentina
Francois Doz, Paris, France
Andrea Ferrari, Milan, Italy
Martha Grootenhuis, Amsterdam, Netherlands
Kathy Pritchard-Jones, London, UK
Lillian Sung, Toronto, Ontario, Canada
Marry van den Heuvel-Eibrink, Rotterdam, Netherlands
Max van Noesel, Rotterdam, Netherlands
GUIDE FOR AUTHORS

INTRODUCTION

The European Journal of Cancer (EJC) is an international multidisciplinary oncology journal, which publishes original research, reviews, and editorial comments on basic and preclinical cancer research, translational oncology, clinical oncology - including medical oncology, paediatric oncology, radiation oncology, and surgical oncology, and cancer epidemiology and prevention.

The EJC is the official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European CanCer Organisation (ECCO) and the European Society of Breast Cancer Specialists (EUSOMA).

Why publish your work in the EJC

Efficient peer-review: The EJC's Editors and reviewers are committed to maintaining the high standards of the journal. All manuscripts submitted to the EJC will be evaluated by the journal's Editors. Some manuscripts may be rejected outright following this evaluation, allowing the authors to submit their work elsewhere. Those manuscripts which are judged as being eligible for consideration by the Editors will be subject to peer-review. The full peer-review policy for the EJC can be found here.

The EJC has an online submission and peer-review system to facilitate the submission and peer-review of submitted manuscripts. Authors are able to upload their manuscript quickly and track the status of their manuscript throughout the review process.

Online Publication as an Article-in-Press: All manuscripts that are accepted for publication in the EJC are published online as Articles-in-Press within 4 - 5 weeks of acceptance. Articles-in-Press can be cited using the unique digital object identifier (DOI) which is assigned to all papers. In addition, Articles-in-Press are indexed in PubMed.

The EJC's readership: The EJC is published in print and online and is available to more than 17,000 academic and clinical institutions, personal subscribers and members of the journal’s Society Partners (the EORTC, ECCO and EUSOMA). In 2011 the journal had more than 83,000 articles downloaded per month from across the world.

The EJC has an iPad app, making each issue of the journal available to our readers in this format. Visit http://itunes.apple.com/us/app/ejc-app/id461022524?mt=8 to find out more.

eTables of Contents: Our readers can elect to receive free eTables of Contents via email, which are sent out for each issue of the journal.

Abstracting and Indexing Coverage: The EJC is included in the leading abstracting and indexing services, including PubMed/MEDLINE, Current Contents/Clinical Medicine, the Science Citation Index, the Journal Citation Reports and Scopus.

HINARI: The EJC is part of HINARI (Health InterNetwork Access to Research Initiative) administered by the World Health Organisation. The HINARI Programme enables developing countries to gain access to one of the world’s largest collections of biomedical and health literature.

Why read the EJC

High quality original research and review articles: The EJC is a multidisciplinary journal, publishing high quality original research and review articles on basic and preclinical research, translational oncology, clinical oncology (medical, paediatric, radiation, surgical), and cancer epidemiology and prevention from across the world.

Guidelines: The EJC is privileged to publish selected treatment guidelines from the journal's Society Partners (the EORTC, ECCO and EUSOMA) and other groups.

Special Series: The EJC publishes special series of papers on linked topics of particular relevance and interest to the journal's readers.
EJC News and EJC News Focus: Each month, the journal publishes the EJC News, discussing and commenting on current issues in cancer, together with the EJC News Focus, a series of video interviews with key opinion leaders in oncology.

**Types of paper**
The EJC will consider the following types of manuscript for publication:

**Editorial comments:** Editorial comments are generally invited by the EJC’s Editorial Team. They are 1,500 words in length with no abstract or keywords.

**Original research articles:** Original research articles have a limit of 2,500 words and no more than 40 references. Authors are asked to provide a structured abstract of no more than 250 words and a list of keywords.

**Review articles:** Review articles have a limit of 3,000 words with an unlimited number of references. Authors are asked to provide an unstructured abstract of no more than 250 words and a list of keywords.

**Current Perspectives:** Current Perspectives have a limit of 2,000 words with an unlimited number of tables and figures and a limit of 30 references. Authors should provide an unstructured abstract of no more than 250 words and a list of keywords.

**Correspondence:** Letters to the Editor which comment directly on work that has previously been published in the EJC will be considered. The author of the paper on which the letter is commenting will be contacted and invited to respond. In addition, the EJC will consider letters on unique cases or observations of interest to the journal’s readership, particularly with regard to side effects from new treatment modalities such as immunotherapy. Letters have a limit of 1,000 words and should be structured as a letter, without an abstract or keywords.

**Contact details for submission**
Manuscripts and the accompanying Author Form should be submitted online at http://ees.elsevier.com/ejc and the instructions on the site should be closely followed. Authors may submit manuscripts and track their progress to final decision. Reviewers can download manuscripts and submit their reports to the Editors.

The full contact details for the Editorial Office are shown below:

European Journal of Cancer
Elsevier Ltd
The Boulevard, Langford Lane
Oxford OX5 1GB
UK
Tel : +44 (0)1865 843282
Fax : +44 (0)1865 843977
Email : ejcancer@elsevier.com

In a covering letter, please identify the person responsible for editorial correspondence (address, telephone and fax numbers and e-mail address).

**Submission checklist**
You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

**Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:
- E-mail address
- Full postal address

All necessary files have been uploaded:

**Manuscript:**
- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
• Indicate clearly if color should be used for any figures in print
  Graphical Abstracts / Highlights files (where applicable)
  Supplemental files (where applicable)

Further considerations
• Manuscript has been 'spell checked' and 'grammar checked'
• All references mentioned in the Reference List are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the Internet)
• A competing interests statement is provided, even if the authors have no competing interests to declare
• Journal policies detailed in this guide have been reviewed
• Referee suggestions and contact details provided, based on journal requirements

For further information, visit our Support Center.

BEFORE YOU BEGIN

Ethics in publishing
Please see our information pages on Ethics in publishing and Ethical guidelines for journal publication.

Human and animal rights
If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans; Uniform Requirements for manuscripts submitted to Biomedical journals. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed.

Declaration of interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If there are no conflicts of interest then please state this: 'Conflicts of interest: none'. More information.

Submission declaration and verification
Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see 'Multiple, redundant or concurrent publication' section of our ethics policy for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck.

Author form
The corresponding author must submit a completed Author Form with their submission. The form enables the corresponding author to record the contribution of each author and confirms whether ethical approval for the study has been sought, whether funding for the study was provided and whether there are any conflicts of interest. It must be signed by the corresponding author and uploaded to EES with the manuscript.
Reporting clinical trials
Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The CONSORT checklist and template flow diagram are available online.

Registration of clinical trials
Registration in a public trials registry is a condition for publication of clinical trials in this journal in accordance with International Committee of Medical Journal Editors recommendations. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. A clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.

Article transfer service
This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. More information.

Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.

For open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (more information). Permitted third party reuse of open access articles is determined by the author’s choice of user license.

Author rights
As an author you (or your employer or institution) have certain rights to reuse your work. More information.

Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.

Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

Microarray data
The data should be made available to our readers/reviewers through a MIAME compliant online database or at least a website address.
Biomarkers

Funding body agreements and policies
Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the Open Access Publication Fee. Details of existing agreements are available online. After acceptance, open access papers will be published under a noncommercial license. For authors requiring a commercial CC BY license, you can apply after your manuscript is accepted for publication.

Open access
This journal offers authors a choice in publishing their research:

**Open access**
- Articles are freely available to both subscribers and the wider public with permitted reuse.
- An open access publication fee is payable by authors or on their behalf, e.g. by their research funder or institution.

**Subscription**
- Articles are made available to subscribers as well as developing countries and patient groups through our universal access programs.
- No open access publication fee payable by authors.

Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards.

For open access articles, permitted third party (re)use is defined by the following Creative Commons user licenses:

*Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)*
For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The open access publication fee for this journal is USD 3700, excluding taxes. Learn more about Elsevier's pricing policy: [http://www.elsevier.com/openaccesspricing](http://www.elsevier.com/openaccesspricing).

Green open access
Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our green open access page for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. [Find out more.](https://www.elsevier.com/embargoperiods)

This journal has an embargo period of 12 months.

Language (usage and editing services)
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop.

Submission
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.
Submit your article
Please submit your article via http://www.ees.elsevier.com/ejc.

Referees
Please submit, with the manuscript, the names, addresses and e-mail addresses of five potential referees. Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.

PREPARATION

Peer review
This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. More information on types of peer review.

Article structure
Please write your text in good English with double line-spacing. Original research manuscripts should be no more than 2,500 words in length, with a maximum of 40 references, and review articles should be no more than 3,000 words in length, with an unlimited number of references. Abstracts should not exceed 250 words in length. Manuscripts may be altered to meet the EJC's style.

Manuscripts containing research data generally follow the order: Introduction, Patients (or Materials) and Methods, Results, and Discussion.

Appendices
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

Essential title page information
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
• Author names and affiliations. Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.
• Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

The title page should also include details of sources of support in the form of grants, equipment, and drugs.

Abstract
The second page should start with the abstract, which should be up to a maximum of 250 words and must include the aim of the study, a brief summary of the methods, results and a concluding statement.

Graphical abstract
Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site.
Authors can make use of Elsevier's Illustration Services to ensure the best presentation of their images and in accordance with all technical requirements.

**Highlights**
Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). You can view example Highlights on our information site.

**Keywords**
Include up to 10 key words from the Medical Subject Headings from *Index Medicus*

**Acknowledgements**
All contributors who do not meet the criteria for authorship as defined by the ICMJE should be listed in an acknowledgments section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair who provided only general support. Authors should disclose whether they had any writing assistance and identify the entity that paid for this assistance.

**Formatting of funding sources**
List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Footnotes**
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

**Artwork**

*Electronic artwork*

**General points**
- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the published version.
- Submit each illustration as a separate file.

A detailed guide on electronic artwork is available.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

**Formats**
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format. Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
- EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.

Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or online only. Further information on the preparation of electronic artwork.

Illustration services
**Elsevier's WebShop** offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

References
**Citation in text**
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

**Data references**
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

**Reference management software**
Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley and Zotero, as well as EndNote. Using the word processor plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide.
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:
http://open.mendeley.com/use-citation-style/european-journal-of-cancer
When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

Reference formatting
There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

Reference style
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.
List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text.
Examples:
Reference to a journal publication:
Reference to a book:
Reference to a chapter in an edited book:
Reference to a website:
Reference to a dataset:
Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6 should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 1997;277:927–34) (see also Samples of Formatted References).

Revised manuscripts
Authors who have been asked to revise their manuscript by the Editors should submit a file which clearly shows the changes that have been made via the 'track changes' function or text highlighting, and a clean copy of the revised manuscript (i.e. a file which contains the changes without any highlighting). Authors are requested not to upload a copy of the original manuscript.

Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

RESEARCH DATA
This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.
Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

**Data linking**

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](#).

For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

**AudioSlides**

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. [More information and examples are available.](#)

Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

**Google Maps and KML files**

KML (Keyhole Markup Language) files (optional): You can enrich your online articles by providing KML or KMZ files which will be visualized using Google maps. The KML or KMZ files can be uploaded in our online submission system. KML is an XML schema for expressing geographic annotation and visualization within Internet-based Earth browsers. Elsevier will generate Google Maps from the submitted KML files and include these in the article when published online. Submitted KML files will also be available for downloading from your online article on ScienceDirect. [More information.](#)

**AFTER ACCEPTANCE**

**Online proof correction**

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

**Offprints**

The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any
time via Elsevier's Webshop. Corresponding authors who have published their article open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

**AUTHOR INQUIRIES**

Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch. You can also check the status of your submitted article or find out when your accepted article will be published.